Block Listing Interim Review

Allergy Therapeutics PLC

02 October 2023

 

Allergy Therapeutics plc

("Allergy Therapeutics", the "Group" or "Company")

Extension of Block Admission

Block Listing Interim Review

2 October 2023 Allergy Therapeutics plc (AIM: AGY) announces that an application has been made to the London Stock Exchange for a block admission of 5,000,000 ordinary shares of 0.1 pence each in the Company ("Ordinary Shares") to be admitted to trading on AIM.

The Ordinary Shares may be issued pursuant to the exercise of share options under Allergy Therapeutics plc 2013 Long Term Incentive Plan and will, upon issue, rank pari passu in all respects with the Company's existing Ordinary Shares. Following this increase, the total Block Listing will consist of 12,013,147 Ordinary Shares.

It is expected that admission will become effective on 5 October 2023. When issued, the Ordinary Shares will rank pari passu with the existing ordinary shares of the Company.

Block Listing Interim Review

Name of applicant:		ALLERGY THERAPEUTICS PLC
Name of scheme:		Allergy Therapeutics plc 2013 Long Term Incentive Plan
Period of return:	From:	1 March 2023	To:	30 September 2023
Number and class of share(s) (amount of stock / debt securities) originally listed and the date of admission:		10,000,000 ordinary shares of 0.1p each in the Company admitted to trading on 24 November 2017 Additional listing of 7,000,000 ordinary shares of 0.1p each in the Company admitted to trading on 7 April 2021
Balance of unallotted securities under scheme(s) from previous return:		7,013,772 ordinary shares*
Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):		Nil
Less:  Number of securities issued/allotted under scheme(s) during period:		Nil
Equals:  Balance under scheme(s) not yet issued/allotted at end of period:		7,013,772 ordinary shares

Name of contact:	Karley Cheesman
Telephone number of contact:	[phone]

*The balance of unallotted securities under the scheme from the previous return has been updated to account for 105,625 ordinary shares that were issued during the previous review period.

For further information, please contact:

Allergy Therapeutics

Manuel Llobet, Chief Executive Officer

Shaun Furlong, Chief Financial Officer

[phone]

Panmure Gordon (Nominated Adviser and Broker)

Emma Earl, Mark Rogers, Freddy Crossley, Corporate Finance

Rupert Dearden, Corporate Broking

[phone]

Consilium Strategic Communications

Mary-Jane Elliott / David Daley / Davide Salvi

[phone]

[e-mail]

Notes for editors:

About Allergy Therapeutics

Allergy Therapeutics is an international commercial biotechnology company, headquartered in the UK, focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third-party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development includes vaccines for grass, tree, house dust mite and peanut. For more information, please see www.allergytherapeutics.com.

 

END